Jonathan Zager
Moffitt Cancer Center · H. Lee Moffitt Cancer Center and Research Institute · H. Lee Moffitt Cancer Center and Research Institue at University of Southern Florida
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jonathan Zager as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:13 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07276386 · Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal MelanomaH. Lee Moffitt Cancer Center and Research Institute · recruiting · Metastatic Uveal Melanoma · principal investigator
- Ph3NCT02678572 · Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular MelanomaDelcath Systems Inc. · completed · Ocular Melanoma, Uveal Melanoma · principal investigator
- Ph2NCT02061007 · Biomarker Correlates of Hypoxia in Metastatic MelanomaH. Lee Moffitt Cancer Center and Research Institute · withdrawn · Melanoma, Skin Cancer · principal investigator
- N/ANCT01728051 · Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to LiverDelcath Systems Inc. · no longer available · Metastatic Liver Cancer, Ocular Melanoma, Cutaneous Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:13 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:13 UTC. The ranking covers the 200 most relevant of 24 PubMed records, and a shared surname and initials can bring in a namesake. All 24 on PubMed
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.J Clin Oncol · 20152,144 citationsRCR 63.6
- 1,082 citationsRCR 38.5
- Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.Ann Surg Oncol · 2016260 citationsRCR 7.8
- Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.Eur J Cancer · 2017163 citationsRCR 4.3
- Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.J Immunother · 2012162 citationsRCR 3.5
- Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases.Ann Surg Oncol · 2016115 citationsRCR 4.3
- Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients.Int J Radiat Oncol Biol Phys · 2012101 citationsRCR 2.5
- Combined analysis of phase III trials evaluating [⁹⁹mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma.Ann Surg Oncol · 2013101 citationsRCR 3.4
- Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma.J Clin Oncol · 201168 citationsRCR 1.7
- Cutaneous angiosarcoma: a single-institution experience.Ann Surg Oncol · 201356 citationsRCR 2.6